What’s in Atossa Genetics Incorporated (NASDAQ:ATOS) After Rise in Shorted Shares?

January 12, 2018 - By Winifred Garcia

 What’s in Atossa Genetics Incorporated (NASDAQ:ATOS) After Rise in Shorted Shares?

The stock of Atossa Genetics Incorporated (NASDAQ:ATOS) registered an increase of 53.46% in short interest. ATOS’s total short interest was 1.96 million shares in January as published by FINRA. Its up 53.46% from 1.28M shares, reported previously. With 993,900 shares average volume, it will take short sellers 2 days to cover their ATOS’s short positions. The short interest to Atossa Genetics Incorporated’s float is 55.98%.

The stock decreased 1.05% or $0.0028 during the last trading session, reaching $0.2641. About 324,579 shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 86.91% since January 12, 2017 and is downtrending. It has underperformed by 103.61% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $8.40 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

More news for Atossa Genetics Inc. (NASDAQ:ATOS) were recently published by: Globenewswire.com, which released: “Atossa Genetics President and CEO Issues Letter to Stockholders Highlighting …” on December 28, 2017. Globenewswire.com‘s article titled: “Atossa Genetics Appoints Carl Novina, MD, PhD as Scientific Advisor” and published on December 21, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: